Passage Bio, a clinical-stage genetic medicines company dedicated to enhancing the lives of patients with neurodegenerative diseases, has announced its participation in two upcoming investor conferences. These events will provide an opportunity for the company’s management to present their cutting-edge therapies and engage with potential investors.
The first conference, the Canaccord Genuity 44th Annual Growth Conference, will take place in Boston, MA on Tuesday, August 13, 2024. Passage Bio’s management will deliver a presentation at 8:00 a.m. ET, followed by investor meetings. This conference serves as a platform for the company to showcase its advancements in the field of neurodegenerative disease treatments.
The second conference, the 15th Annual Wedbush PacGrow Healthcare Conference, will be held in New York City, NY on Wednesday, August 14, 2024. Passage Bio’s management will participate in investor meetings during this event. The company aims to leverage this conference to further highlight its commitment to developing one-time therapies that target the underlying pathology of neurodegenerative conditions.
Passage Bio’s lead product candidate, PBFT02, is specifically designed to address neurodegenerative conditions, including frontotemporal dementia. By elevating progranulin levels, PBFT02 aims to restore lysosomal function and slow disease progression. The company’s focus on developing innovative therapies demonstrates its steadfast dedication to protecting patients and families affected by neurodegenerative diseases.
Investors and interested individuals can access a live webcast of Passage Bio’s presentation on the Investors & Media section of the company’s website at investors.passagebio.com. Additionally, a replay of the presentation will be available for 30 days after the event.
To learn more about Passage Bio and its groundbreaking work in the field of neurodegenerative diseases, visit their website at www.passagebio.com. For further information or inquiries, please contact Stuart Henderson, Passage Bio’s representative, at shenderson@passagebio.com or call 267.866.0114.